October 15, 2026

AI may predict focal GBM recurrence

Optical analysis of resection-margin tissue identified tumor infiltration as the strongest contributor to predictions of where glioblastoma later recurred.

MDSpire News

October 05, 2026

Rare GI disease leads to 20-plus units of transfused blood

A rare intestinal lymphangioma caused life-threatening bleeding without typical laboratory features of protein-losing enteropathy

MDSpire News

September 24, 2026

FDA approves combo for advanced renal cell carcinoma

Median progression-free survival was 15 months with the combination vs. 11 months with cabozantinib in the LITESPARK-011 trial.

MDSpire News

September 24, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

MDSpire News

September 18, 2026

Retained silk may underlie late postvasectomy fistula

Surgery and histopathology identified retained silk ligature with chronic inflammation at the site of a rare fistula presenting 3 years following vasectomy.

MDSpire News

September 16, 2026

Hot drink habits and esophageal cancer

Researchers assessed preferred hot drink temperature and consumption frequency across 2 large UK cohorts.

MDSpire News

September 15, 2026

Photodynamic therapy gains FDA approval for superficial BCC

Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.

MDSpire News

September 10, 2026

Fibrinogen cryptokines may promote steroid-resistant asthma

Low-dose lipopolysaccharide and fungal airway exposure were linked to persistent airway hyperresponsiveness despite glucocorticoid treatment in experimental models.

MDSpire News

August 26, 2026

Neurogenic progression may falter in MDD

Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.

MDSpire News

August 25, 2026

FDA expands gastroesophageal cancer options

Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.

MDSpire News